Tom 10, Supl. F (2024)
Opis przypadku
Opublikowany online: 2024-11-07
Wyświetlenia strony
21
Wyświetlenia/pobrania artykułu
5
Długotrwała odpowiedź na chemioimmunoterapię u pacjenta w podeszłym wieku z rozpoznaniem zaawansowanego drobnokomórkowego raka płuca
1
Streszczenie
Drobnokomórkowy rak płuca jest chorobą o złym rokowaniu. W ostatnich latach wskutek wprowadzenia immunoterapii dokonał się przełom w leczeniu systemowym chorych z rozległą postacią choroby. Durwalumab jest lekiem z grupy inhibitorów punktów kontrolnych (ICIs, immune checkpoint inhibitors), który w skojarzeniu z chemioterapią poprawia rokowanie w tej grupie chorych.
W niniejszej pracy opisano przypadek chorego w podeszłym wieku, u którego dzięki zastosowaniu chemioimmunoterapii osiągnięto długotrwałą remisję choroby przy bardzo dobrej tolerancji leczenia.
Słowa kluczowe: durwalumabrak płucaDRPimmunoterapia
Referencje
- Goldman JW, Dvorkin M, Chen Y, et al. CASPIAN investigators, CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019; 394(10212): 1929–1939.
- Paz-Ares L, Chen Y, Reinmuth N, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022; 7(2): 100408.
- Saito H, Goldman J, Garassino M, et al. O11-5 Durvalumab(D) ± tremelimumab(T) + platinum-etoposide(EP) in 1L ES-SCLC: Characterization of long-term benefit in CASPIAN. Ann Oncol. 2021; 32: S289.
- Chen Y, Paz-Ares L, Reinmuth N, et al. Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report. JTO Clin Res Rep. 2022; 3(6): 100330.
- Reinmuth N, Goldman JW, Chen Y, et al. 1530P Durvalumab (D) + platinum-etoposide (EP) in first-line extensive-stage SCLC (ES SCLC): Effect of age and platinum agent on outcomes in CASPIAN. Ann Oncol. 2022; 33(suppl_7): S1245–S1246.
- Horn L, Mansfield AS, Szczęsna A, et al. IMpower133 Study Group. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018; 379(23): 2220–2229.
- Kim HR, Awad MM, Navarro A, et al. KEYNOTE-604 Investigators. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. J Clin Oncol. 2020; 38(21): 2369–2379.
- Besse B, Menis J, Bironzo P, et al. LBA85 REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer. Ann Oncol. 2020; 31: S1211–S1212.
- Behera M, Ragin C, Kim S, et al. Trends, predictors, and impact of systemic chemotherapy in small cell lung cancer patients between 1985 and 2005. Cancer. 2016; 122(1): 50–60.
- Montella T, Vasco M, Silva A, et al. Evaluation of elderly patients with extended disease small-cell lung cancer. J Clin Oncol. 2013; 31(15_suppl): e18515–e18515.
- Facchinetti F, Mazzaschi G, Barbieri F, et al. First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status. Eur J Cancer. 2020; 130: 155–167.
- Muchnik E, Loh KP, Strawderman M, et al. Immune Checkpoint Inhibitors in Real-World Treatment of Older Adults with Non-Small Cell Lung Cancer. J Am Geriatr Soc. 2019; 67(5): 905–912.
- Janssen-Heijnen MLG, Maas HA, van de Schans SAM, et al. Chemotherapy in elderly small-cell lung cancer patients: yes we can, but should we do it? Ann Oncol. 2011; 22(4): 821–826.
- Montrone M, Rosati G, Longo V, et al. Immunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review. J Clin Med. 2023; 12(5).
- National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Older Adult Oncology. Version 1.2023. 2024. https://www.nccn.org/professionals/physician_gls/pdf/older_adult.pdf.
- van Walree IC, Scheepers E, van Huis-Tanja L, et al. A systematic review on the association of the G8 with geriatric assessment, prognosis and course of treatment in older patients with cancer. J Geriatr Oncol. 2019; 10(6): 847–858.
- Li D, Sun CL, Kim H, et al. Geriatric Assessment-Driven Intervention (GAIN) on Chemotherapy-Related Toxic Effects in Older Adults With Cancer: A Randomized Clinical Trial. JAMA Oncol. 2021; 7(11): e214158.
- Gay CM, Stewart CA, Park EM, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021; 39(3): 346–360.e7.
- Nabet B, Hamidi H, Banchereau R, et al. 523 Small cell lung cancer molecular subtypes and vulnerability to immune checkpoint blockade. Regular and Young Investigator Award Abstracts. 2022: A549–A549.
- Xie M, Chugh P, Broadhurst H, et al. Durvalumab + platinum-etoposide in first-line extensive-stage small cell lung cancer (ES-SCLC): exploratory analysis of SCLC molecular subtypes in CASPIAN. Presented at: 2022 AACR Annual Meeting April 8-13, 2022. New Orleans, LA. Abstract CT024.
